Biopharmaceutical company Liquidia Corporation (NASDAQ: LQDA) reported a profit for the fourth quarter of fiscal 2025, compared to a loss last year, as it began shipping its lead product to customers in the US.
Liquidia reported net income of $14.6 million or $0.15 per share for the fourth quarter, compared to a loss of $38.5 million or $0.45 per share in the comparable period last year.
Driving strong bottom-line performance, total revenues surged to $92.02 million in Q4 from $2.9 million in the fourth quarter of FY24, when the company had not yet launched a commercial product. The company ended 2025 with $190.7 million in cash and cash equivalents, representing a $33.2 million sequential growth.
Product revenue totaled $90.0 million, and services revenue came in at $1.92 million. YUTREPIA, the company’s lead product that was commercially launched in June last year, has received more than 3,600 unique patient prescriptions so far and has started more than 2,900 patients on treatment.
“As we close 2025, we are encouraged by how quickly YUTREPIA has taken hold in clinical practice, placing it among one of the top specialty drug launches over the past five years across all therapeutic categories. Adoption continues to broaden across PAH and PH-ILD, with increasing depth in treatment centers and more experience transitioning appropriate patients from oral, inhaled, and systemic prostacyclin therapies,” said Roger Jeffs, Liquidia’s CEO.
The post Liquidia Corporation (LQDA) swings to profit in Q4 FY25 on strong revenue growth first appeared on AlphaStreet News.
